Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Topiramate add-on therapy for drug-resistant focal epilepsy.

Bresnahan R, Hounsome J, Jette N, Hutton JL, Marson AG.

Cochrane Database Syst Rev. 2019 Oct 23;10:CD001417. doi: 10.1002/14651858.CD001417.pub4. [Epub ahead of print] Review.

PMID:
31642054
2.

Tiagabine add-on therapy for drug-resistant focal epilepsy.

Bresnahan R, Martin-McGill KJ, Hutton JL, Marson AG.

Cochrane Database Syst Rev. 2019 Oct 14;10:CD001908. doi: 10.1002/14651858.CD001908.pub4. [Epub ahead of print] Review.

PMID:
31608990
3.

Gabapentin add-on treatment for drug-resistant focal epilepsy.

Panebianco M, Al-Bachari S, Weston J, Hutton JL, Marson AG.

Cochrane Database Syst Rev. 2018 Oct 24;10:CD001415. doi: 10.1002/14651858.CD001415.pub3.

4.

Burke-Fahn-Marsden dystonia severity, Gross Motor, Manual Ability, and Communication Function Classification scales in childhood hyperkinetic movement disorders including cerebral palsy: a 'Rosetta Stone' study.

Elze MC, Gimeno H, Tustin K, Baker L, Lumsden DE, Hutton JL, Lin JP.

Dev Med Child Neurol. 2016 Feb;58(2):145-53. doi: 10.1111/dmcn.12965. Epub 2015 Nov 30.

5.

Weighing privacy against effective epidemiology.

Hutton JL.

Dev Med Child Neurol. 2015 Jul;57(7):595-596. doi: 10.1111/dmcn.12756. Epub 2015 Apr 1. No abstract available.

6.

Dendritic cell reconstitution is associated with relapse-free survival and acute GVHD severity in children after allogeneic stem cell transplantation.

Elze MC, Ciocarlie O, Heinze A, Kloess S, Gardlowski T, Esser R, Klingebiel T, Bader P, Huenecke S, Serban M, Köhl U, Hutton JL.

Bone Marrow Transplant. 2015 Feb;50(2):266-73. doi: 10.1038/bmt.2014.257. Epub 2014 Nov 10.

PMID:
25387093
7.

Topiramate add-on for drug-resistant partial epilepsy.

Pulman J, Jette N, Dykeman J, Hemming K, Hutton JL, Marson AG.

Cochrane Database Syst Rev. 2014 Feb 25;(2):CD001417. doi: 10.1002/14651858.CD001417.pub3. Review.

PMID:
24570033
8.

Tiagabine add-on for drug-resistant partial epilepsy.

Pulman J, Hutton JL, Marson AG.

Cochrane Database Syst Rev. 2014 Feb 5;(2):CD001908. doi: 10.1002/14651858.CD001908.pub3. Review.

9.

The adverse effects profile of levetiracetam in epilepsy: a more detailed look.

Mbizvo GK, Dixon P, Hutton JL, Marson AG.

Int J Neurosci. 2014 Sep;124(9):627-34. doi: 10.3109/00207454.2013.866951. Epub 2013 Dec 18. Review.

PMID:
24256446
10.

Gabapentin add-on for drug-resistant partial epilepsy.

Al-Bachari S, Pulman J, Hutton JL, Marson AG.

Cochrane Database Syst Rev. 2013 Jul 25;(7):CD001415. doi: 10.1002/14651858.CD001415.pub2. Review. Update in: Cochrane Database Syst Rev. 2018 Oct 24;10:CD001415.

PMID:
23888424
11.

Vigabatrin for refractory partial epilepsy.

Hemming K, Maguire MJ, Hutton JL, Marson AG.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD007302. doi: 10.1002/14651858.CD007302.pub2. Review.

PMID:
23440814
12.

Age-matched dendritic cell subpopulations reference values in childhood.

Heinze A, Elze MC, Kloess S, Ciocarlie O, Königs C, Betz S, Bremm M, Esser R, Klingebiel T, Serban M, Hutton JL, Koehl U.

Scand J Immunol. 2013 Mar;77(3):213-20. doi: 10.1111/sji.12024.

13.

Letter commenting on 'Survival after short- or long-term ventilation after acute spinal cord injury: a single-centre 25-year retrospective study'.

Hutton JL, Watt JH, Wiredu E.

Spinal Cord. 2012 Nov;50(11):859-60. doi: 10.1038/sc.2012.106. Epub 2012 Sep 25. No abstract available.

PMID:
23007115
14.

Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review.

Mbizvo GK, Dixon P, Hutton JL, Marson AG.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD001901. doi: 10.1002/14651858.CD001901.pub2. Review.

PMID:
22972056
15.

Tiagabine add-on for drug-resistant partial epilepsy.

Pulman J, Marson AG, Hutton JL.

Cochrane Database Syst Rev. 2012 May 16;(5):CD001908. doi: 10.1002/14651858.CD001908.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(2):CD001908.

16.

Statistician expert witnesses in agreement on relative hazards.

Bird SM, Hutton JL.

Clin Risk. 2012 Mar;18(2):58-62.

17.

Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.

Kimani PK, Glimm E, Maurer W, Hutton JL, Stallard N.

Stat Med. 2012 Aug 30;31(19):2068-85. doi: 10.1002/sim.5326. Epub 2012 Mar 22.

PMID:
22437262
18.

Fetal growth and birthweight standards as screening tools: methods for evaluating performance.

Hemming K, Bonellie S, Hutton JL.

BJOG. 2011 Nov;118(12):1477-83. doi: 10.1111/j.1471-0528.2011.03067.x. Epub 2011 Jul 27.

19.

Changes in rates of violent child deaths in England and Wales between 1974 and 2008: an analysis of national mortality data.

Sidebotham P, Atkins B, Hutton JL.

Arch Dis Child. 2012 Mar;97(3):193-9. doi: 10.1136/adc.2010.207647. Epub 2011 Apr 27.

PMID:
21525527
20.

Modelling the rate of change in a longitudinal study with missing data, adjusting for contact attempts.

Akacha M, Hutton JL.

Stat Med. 2011 May 10;30(10):1072-89. doi: 10.1002/sim.4165. Epub 2011 Feb 1.

PMID:
21284012
21.

Bayesian sensitivity models for missing covariates in the analysis of survival data.

Hemming K, Hutton JL.

J Eval Clin Pract. 2012 Apr;18(2):238-46. doi: 10.1111/j.1365-2753.2010.01569.x. Epub 2010 Nov 30.

PMID:
21114712
22.

Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.

Maguire MJ, Hemming K, Wild JM, Hutton JL, Marson AG.

Epilepsia. 2010 Dec;51(12):2423-31. doi: 10.1111/j.1528-1167.2010.02772.x. Epub 2010 Nov 10. Review.

23.

Modelling bounded health scores with censored skew-normal distributions.

Hutton JL, Stanghellini E.

Stat Med. 2011 Feb 20;30(4):368-76. doi: 10.1002/sim.4104.

PMID:
21058361
24.

Meta-regression with partial information on summary trial or patient characteristics.

Hemming K, Hutton JL, Maguire MG, Marson AG.

Stat Med. 2010 May 30;29(12):1312-24. doi: 10.1002/sim.3848.

PMID:
20087842
25.

Yeast Sec1p functions before and after vesicle docking.

Hashizume K, Cheng YS, Hutton JL, Chiu CH, Carr CM.

Mol Biol Cell. 2009 Nov;20(22):4673-85. doi: 10.1091/mbc.E09-02-0172. Epub 2009 Sep 23.

26.

A comparison of customized and population-based birth-weight standards: the influence of gestational age.

Hemming K, Hutton JL, Bonellie S.

Eur J Obstet Gynecol Reprod Biol. 2009 Sep;146(1):41-5. doi: 10.1016/j.ejogrb.2009.05.033. Epub 2009 Jul 5.

PMID:
19581044
27.

Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials.

Hutton JL.

Br J Haematol. 2009 Jun;146(1):27-30. doi: 10.1111/j.1365-2141.2009.07707.x. Epub 2009 Apr 27. Review.

PMID:
19438480
28.

Treatment of severe ankle sprain: a pragmatic randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of three types of mechanical ankle support with tubular bandage. The CAST trial.

Cooke MW, Marsh JL, Clark M, Nakash R, Jarvis RM, Hutton JL, Szczepura A, Wilson S, Lamb SE; CAST trial group.

Health Technol Assess. 2009 Feb;13(13):iii, ix-x, 1-121. doi: 10.3310/hta13130.

29.

Mechanical supports for acute, severe ankle sprain: a pragmatic, multicentre, randomised controlled trial.

Lamb SE, Marsh JL, Hutton JL, Nakash R, Cooke MW; Collaborative Ankle Support Trial (CAST Group).

Lancet. 2009 Feb 14;373(9663):575-81. doi: 10.1016/S0140-6736(09)60206-3.

PMID:
19217992
30.

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

Kimani PK, Stallard N, Hutton JL.

Stat Med. 2009 Mar 15;28(6):917-36. doi: 10.1002/sim.3522.

PMID:
19152231
31.

Ethical issues in implementation research: a discussion of the problems in achieving informed consent.

Hutton JL, Eccles MP, Grimshaw JM.

Implement Sci. 2008 Dec 17;3:52. doi: 10.1186/1748-5908-3-52.

32.

Intrapartum amnioinfusion for meconium-stained amniotic fluid: evidence for small study effect bias?

Hemming K, Hutton JL.

BJOG. 2009 Jan;116(1):128-9. doi: 10.1111/j.1471-0528.2008.02011.x. No abstract available.

33.

Vigabatrin for refractory partial epilepsy.

Hemming K, Maguire MJ, Hutton JL, Marson AG.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD007302. doi: 10.1002/14651858.CD007302. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD007302.

PMID:
18646179
34.

Topiramate add-on for drug-resistant partial epilepsy.

Jette N, Hemming K, Hutton JL, Marson AG.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001417. doi: 10.1002/14651858.CD001417.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;2:CD001417.

PMID:
18646072
35.

The influence of gestational age on severity of impairment in spastic cerebral palsy.

Hemming K, Colver A, Hutton JL, Kurinczuk JJ, Pharoah PO.

J Pediatr. 2008 Aug;153(2):203-8, 208.e1-4. doi: 10.1016/j.jpeds.2008.02.041. Epub 2008 Apr 23.

PMID:
18534232
36.

Overwhelming heterogeneity in systematic reviews of observational anti-epileptic studies.

Maguire MJ, Hemming K, Hutton JL, Marson AG.

Epilepsy Res. 2008 Aug;80(2-3):201-12. doi: 10.1016/j.eplepsyres.2008.03.024. Epub 2008 Jun 2. Review.

PMID:
18515046
37.

Reporting and analysis of open-label extension studies of anti-epileptic drugs.

Maguire MJ, Hemming K, Hutton JL, Marson AG.

Epilepsy Res. 2008 Sep;81(1):24-9. doi: 10.1016/j.eplepsyres.2008.04.007. Epub 2008 Jun 2. Review.

PMID:
18514485
38.

Open label extension studies and patient selection biases.

Hemming K, Hutton JL, Maguire MJ, Marson AG.

J Eval Clin Pract. 2008 Feb;14(1):141-4. doi: 10.1111/j.1365-2753.2007.00821.x.

PMID:
18211657
39.

Response and non-response to postal questionnaire follow-up in a clinical trial--a qualitative study of the patient's perspective.

Nakash RA, Hutton JL, Lamb SE, Gates S, Fisher J.

J Eval Clin Pract. 2008 Apr;14(2):226-35. Epub 2007 Dec 13.

PMID:
18093103
40.

Intrauterine growth and survival in cerebral palsy.

Hemming K, Hutton JL, Bonellie S, Kurinczuk JJ.

Arch Dis Child Fetal Neonatal Ed. 2008 Mar;93(2):F121-6. Epub 2007 Sep 12.

PMID:
17855446
41.
42.
43.

Taste and smell abnormalities as an independent cause of failure of food intake in patients with advanced cancer--an argument for the application of sensory science.

Brisbois TD, Hutton JL, Baracos VE, Wismer WV.

J Palliat Care. 2006 Summer;22(2):111-4. Review. No abstract available.

PMID:
17265664
44.

Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy.

Hutton JL, Martin L, Field CJ, Wismer WV, Bruera ED, Watanabe SM, Baracos VE.

Am J Clin Nutr. 2006 Nov;84(5):1163-70.

PMID:
17093170
45.

Differences between European birthweight standards: impact on classification of 'small for gestational age'.

Hemming K, Hutton JL, Glinianaia SV, Jarvis SN, Platt MJ.

Dev Med Child Neurol. 2006 Nov;48(11):906-12.

46.

Cerebral palsy life expectancy.

Hutton JL.

Clin Perinatol. 2006 Jun;33(2):545-55. Review.

PMID:
16765736
47.

Maximising response to postal questionnaires--a systematic review of randomised trials in health research.

Nakash RA, Hutton JL, Jørstad-Stein EC, Gates S, Lamb SE.

BMC Med Res Methodol. 2006 Feb 23;6:5. Review.

48.

Life expectancy in severe cerebral palsy.

Hutton JL, Pharoah PO.

Arch Dis Child. 2006 Mar;91(3):254-8. Review.

49.

Long-term survival for a cohort of adults with cerebral palsy.

Hemming K, Hutton JL, Pharoah PO.

Dev Med Child Neurol. 2006 Feb;48(2):90-5.

50.

Regional variation in survival of people with cerebral palsy in the United Kingdom.

Hemming K, Hutton JL, Colver A, Platt MJ.

Pediatrics. 2005 Dec;116(6):1383-90.

PMID:
16322162

Supplemental Content

Loading ...
Support Center